Skip to main content

letter

. 2001 Mar;26(2):152–153.

Gynecomastia induced by treatment with tandospirone, a 5-HT1A agonist.

Y Kaneda, T Morimoto, A Fujii

PMCID: PMC1407752 PMID: 11291533

152

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bhatia S. C., Gupta S., Theesen K. A. Breast pain associated with venlafaxine. J Clin Psychiatry. 1996 Sep;57(9):423–423. [PubMed] [Google Scholar]
Carlson H. E. Gynecomastia. N Engl J Med. 1980 Oct 2;303(14):795–799. doi: 10.1056/NEJM198010023031405. [DOI] [PubMed] [Google Scholar]
Franks S., Jacobs H. S., Martin N., Nabarro J. D. Hyperprolactinaemia and impotence. Clin Endocrinol (Oxf) 1978 Apr;8(4):277–287. doi: 10.1111/j.1365-2265.1978.tb02770.x. [DOI] [PubMed] [Google Scholar]
Shimizu H., Hirose A., Tatsuno T., Nakamura M., Katsube J. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn J Pharmacol. 1987 Dec;45(4):493–500. doi: 10.1254/jjp.45.493. [DOI] [PubMed] [Google Scholar]
Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf. 1999 Mar;20(3):277–287. doi: 10.2165/00002018-199920030-00007. [DOI] [PubMed] [Google Scholar]
Thompson D. F., Carter J. R. Drug-induced gynecomastia. Pharmacotherapy. 1993 Jan-Feb;13(1):37–45. [PubMed] [Google Scholar]

ACTIONS

PDF (488.2 KB)

RESOURCES